Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain to Use N-of-One's Clinical Interpretation Service for Oncology

NEW YORK (GenomeWeb) – N-of-One said today that it will provide clinical interpretation services to Intermountain Healthcare as part of the hospital system's oncology precision medicine services program.

Under the terms of the agreement, N-of-One will handle the interpretation of cancer patients' next-generation sequencing test results. Using its platform, the firm will link relevant biological and clinical knowledge to the mutation profiles of tumors and help oncologists identify more effective therapeutic strategies for their patients.

Intermountain tapped N-of-One's service for its tumor test offering because of the firm's "oncology domain expertise combined with their flexible and efficient delivery capabilities," Lincoln Nadauld, director of cancer genomics at Intermountain Healthcare, said in a statement. The interpretation services will enable "us to implement a premier precision medicine program which better serves the needs of a broad range of oncologists and their patients," he said.

Financial terms of the agreement were not disclosed.
Intermountain is a non-profit health system based in Salt Lake City that includes 22 hospitals and around 1,100 primary care and secondary care physicians at more than 185 clinics. Earlier this year, it inked a deal with Syapse to provide oncologists with access to tumor genome profiling, data analysis, and drug procurement services.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.